医学
氯氮平
阿立哌唑
精神科
精神分裂症(面向对象编程)
非定型抗精神病薬
抗精神病药
利培酮
药物治疗
重症监护医学
作者
Justina A. Warnick,Rachel I. Gifeisman,K Joshi,Sophie A. Roe,Rick A. Hiciano,Christopher P. Conroy,Sohrab Zahedi
标识
DOI:10.1089/jchc.23.09.0079
摘要
Treatment-resistant schizophrenia (TRS) is a challenging condition to treat for the correctional psychiatrist. Guidelines from the American Psychiatric Association indicate that the first-line pharmacotherapy for TRS is the use of the atypical antipsychotic clozapine. The use of clozapine is unique in that it requires patient adherence with weekly blood draws as a prophylactic measure against agranulocytosis and leukopenia. In the correctional setting, patients with severe and persistent schizophrenia are frequently nonadherent due to lack of insight and anemic access to health care resources, specifically as these pertain to clozapine. Therefore, an alternative treatment option would be a welcome solution for this demographic. Our literature review demonstrates a limited number of studies documenting the successful use of clozapine alternatives or combination antipsychotic therapy for treatment of TRS. In this article, we present a putative case where we believe that a combination regimen of paliperidone palmitate, oral aripiprazole, and escitalopram led to a notable mitigation of both positive and negative symptoms of psychosis in the case of an incarcerated patient with TRS, as well as an improvement in functional stability, which was conducive to housing in a less restrictive setting. A brief review of the published literature follows the report.
科研通智能强力驱动
Strongly Powered by AbleSci AI